GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Debt-to-EBITDA

SanBio Co (TSE:4592) Debt-to-EBITDA : -0.21 (As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SanBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円268.00 Mil. SanBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円397.00 Mil. SanBio Co's annualized EBITDA for the quarter that ended in Jan. 2024 was 円-3,191.04 Mil. SanBio Co's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SanBio Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4592' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.42   Med: -0.6   Max: 0.54
Current: -0.26

During the past 11 years, the highest Debt-to-EBITDA Ratio of SanBio Co was 0.54. The lowest was -1.42. And the median was -0.60.

TSE:4592's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs TSE:4592: -0.26

SanBio Co Debt-to-EBITDA Historical Data

The historical data trend for SanBio Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Debt-to-EBITDA Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.79 -1.30 -0.58 -0.20 -0.26

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.25 -0.20 1.53 -0.21

Competitive Comparison of SanBio Co's Debt-to-EBITDA

For the Biotechnology subindustry, SanBio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SanBio Co's Debt-to-EBITDA falls into.



SanBio Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SanBio Co's Debt-to-EBITDA for the fiscal year that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(268 + 397) / -2517.083
=-0.26

SanBio Co's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(268 + 397) / -3191.04
=-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


SanBio Co  (TSE:4592) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


SanBio Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SanBio Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (TSE:4592) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines